1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Boutin AT, Liao WT, Wang M, Hwang SS,
Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, et al:
Oncogenic Kras drives invasion and maintains metastases in
colorectal cancer. Genes Dev. 31:370–382. 2017. View Article : Google Scholar : PubMed/NCBI
|
3
|
Taieb J, Le Malicot K, Shi Q, Penault
Lorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G,
Luc Van Laethem J, et al: Prognostic value of BRAF and KRAS
mutations in MSI and MSS stage III colon cancer. J Natl Cancer
Inst. 109:pii: djw2722016. View Article : Google Scholar
|
4
|
Yi R, Li Y, Wang FL, Miao G, Qi RM and
Zhao YY: MicroRNAs as diagnostic and prognostic biomarkers in
colorectal cancer. World J Gastrointest Oncol. 8:330–340. 2016.
View Article : Google Scholar : PubMed/NCBI
|
5
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ, et al: A microRNA polycistron as a potential human
oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lanza G, Ferracin M, Gafà R, Veronese A,
Spizzo R, Pichiorri F, Liu CG, Calin GA, Croce CM and Negrini M:
mRNA/microRNA gene expression profile in microsatellite unstable
colorectal cancer. Mol Cancer. 6:542007. View Article : Google Scholar : PubMed/NCBI
|
7
|
Diosdado B, van de Wiel MA, Terhaar Sive
Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B and Meijer
GA: MiR-17-92 cluster is associated with 13q gain and c-myc
expression during colorectal adenoma to adenocarcinoma progression.
Br J Cancer. 101:707–714. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Ma H, Pan JS, Jin LX, Wu J, Ren YD, Chen
P, Xiao C and Han J: MicroRNA-17~92 inhibits colorectal cancer
progression by targeting angiogenesis. Cancer Lett. 376:293–302.
2016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Olive V, Bennett MJ, Walker JC, Ma C,
Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ and He L: miR-19
is a key oncogenic component of mir-17-92. Genes Dev. 23:2839–2849.
2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Yamamoto K, Ito S, Hanafusa H, Shimizu K
and Ouchida M: Uncovering direct targets of miR-19a involved in
lung cancer progression. PLoS One. 10:e01378872015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lu WD, Zuo Y, Xu Z and Zhang M: MiR-19a
promotes epithelial-mesenchymal transition through PI3K/AKT pathway
in gastric cancer. World J Gastroenterol. 21:4564–4573. 2015.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhang J, Xiao Z, Lai D, Sun J, He C, Chu
Z, Ye H, Chen S and Wang J: miR-21, miR-17 and miR-19a induced by
phosphatase of regenerating liver-3 promote the proliferation and
metastasis of colon cancer. Br J Cancer. 107:352–359. 2012.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Landskroner-Eiger S, Qiu C, Perrotta P,
Siragusa M, Lee MY, Ulrich V, Luciano AK, Zhuang ZW, Corti F,
Simons M, et al: Endothelial miR-17~92 cluster negatively regulates
arteriogenesis via miRNA-19 repression of WNT signaling. Proc Natl
Acad Sci USA. 112:pp. 12812–12817. 2015; View Article : Google Scholar : PubMed/NCBI
|
14
|
Cellura D, Pickard K, Quaratino S, Parker
H, Strefford JC, Thomas GJ, Mitter R, Mirnezami AH and Peake NJ:
miR-19-mediated inhibition of transglutaminase-2 leads to enhanced
invasion and metastasis in colorectal cancer. Mol Cancer Res.
13:1095–1105. 2015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Yu G, Li H, Wang X, Wu T, Zhu J, Huang S,
Wan Y and Tang J: MicroRNA-19a targets tissue factor to inhibit
colon cancer cells migration and invasion. Mol Cell Biochem.
380:239–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Xiao C, Calado DP, Galler G, Thai TH,
Patterson HC, Wang J, Rajewsky N, Bender TP and Rajewsky K: MiR-150
controls B cell differentiation by targeting the transcription
factor c-Myb. Cell. 165:10272016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
18
|
Guo H, Jia Y, Shang M, Zhang Y, Xie F,
Wang H, Yuan M, Yuan L and Ye J: Comparison of two in vitro
angiogenesis assays for evaluating the effects of netrin-1 on tube
formation. Acta Biochim Biophys Sin. 46:810–816. 2014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Ponce ML: Tube formation: An in vitro
matrigel angiogenesis assay. Methods Mol Biol. 467:183–188. 2009.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Simons M and Eichmann A: Molecular
controls of arterial morphogenesis. Circ Res. 116:1712–1724. 2015.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Yeh YW, Cheng CC, Yang ST, Tseng CF, Chang
TY, Tsai SY, Fu E, Chiang CP, Liao LC, Tsai PW, et al: Targeting
the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis
and stemness via inhibition of KRAS/YAP1 signaling. Oncotarget.
8:5603–5618. 2017.PubMed/NCBI
|
22
|
Chakraborty C, Sharma AR, Patra BC,
Bhattacharya M, Sharma G and Lee SS: MicroRNAs mediated regulation
of MAPK signaling pathways in chronic myeloid leukemia. Oncotarget.
7:42683–42697. 2016. View Article : Google Scholar : PubMed/NCBI
|
23
|
Doebele C, Bonauer A, Fischer A, Scholz A,
Reiss Y, Urbich C, Hofmann WK, Zeiher AM and Dimmeler S: Members of
the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic
function in endothelial cells. Blood. 115:4944–4950. 2010.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Mihalache A and Rogoveanu I: Angiogenesis
factors involved in the pathogenesis of colorectal cancer. Curr
Health Sci J. 40:5–11. 2014.PubMed/NCBI
|
25
|
Shinkaruk S, Bayle M, Laïn G and Déléris
G: Vascular endothelial cell growth factor (VEGF), an emerging
target for cancer chemotherapy. Curr Med Chem Anticancer Agents.
3:95–117. 2003. View Article : Google Scholar : PubMed/NCBI
|
26
|
Ikeda N, Nakajima Y, Sho M, Adachi M,
Huang CL, Iki K, Kanehiro H, Hisanaga M, Nakano H and Miyake M: The
association of K-ras gene mutation and vascular endothelial growth
factor gene expression in pancreatic carcinoma. Cancer. 92:488–499.
2001. View Article : Google Scholar : PubMed/NCBI
|
27
|
Qiu Y, Yu H, Shi X, Xu K, Tang Q, Liang B,
Hu S, Bao Y, Xu J, Cai J, et al: microRNA-497 inhibits invasion and
metastasis of colorectal cancer cells by targeting vascular
endothelial growth factor-A. Cell Prolif. 49:69–78. 2016.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Matsuo Y, Campbell PM, Brekken RA, Sung B,
Ouellette MM, Fleming JB, Aggarwal BB, Der CJ and Guha S: K-Ras
promotes angiogenesis mediated by immortalized human pancreatic
epithelial cells through mitogen-activated protein kinase signaling
pathways. Mol Cancer Res. 7:799–808. 2009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Ren J, Li G, Ge J, Li X and Zhao Y: Is
K-ras gene mutation a prognostic factor for colorectal cancer: A
systematic review and meta-analysis. Dis Colon Rectum. 55:913–923.
2012. View Article : Google Scholar : PubMed/NCBI
|
30
|
Tsuchida N, Murugan AK and Grieco M:
Kirsten Ras* oncogene: Significance of its discovery in human
cancer research. Oncotarget. 7:46717–46733. 2016. View Article : Google Scholar : PubMed/NCBI
|
31
|
Deng Y, Wang L, Tan S, Kim GP, Dou R, Chen
D, Cai Y, Fu X, Wang L, Zhu J, et al: KRAS as a predictor of poor
prognosis and benefit from postoperative FOLFOX chemotherapy in
patients with stage II and III colorectal cancer. Mol Oncol.
9:1341–1347. 2015. View Article : Google Scholar : PubMed/NCBI
|
32
|
Gil Ferreira C, Aran V, Zalcberg-Renault
I, Victorino AP, Salem JH, Bonamino MH, Vieira FM and Zalis M: KRAS
mutations: Variable incidences in a Brazilian cohort of 8,234
metastatic colorectal cancer patients. BMC Gastroenterol.
14:732014. View Article : Google Scholar : PubMed/NCBI
|
33
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|